Skip to main content
. 2022 Jan 6;39:100921. doi: 10.1016/j.gore.2022.100921

Table 2.

Clinical outcomes.

Present series N = 4* Compiled data (%) 19722018 (Noh J etal)4,N = 37
No evidence of disease after treatment** 2 21(57%)
Recurred 1 14 (38%)
Interval to recurrence
(months)
63 Median 6.5 (Range 1–48)
Site of recurrence Lung and chest wall −1 Lung – 5 (36%)
Lymph node − 8 (57%)
Local recurrence − 4 (20%)
Others − 2 (14%)
Died of disease 0 14 (38%)
*

One patient is undergoing upfront palliative treatment.